Editor, Ophthalmology Times
ARVO LIVE: Using mitochondria, senolytic agents to treat retinal injury
May 3rd 2023Ram Kannan, PhD, FARVO, principal investigator and adjunct professor of Ophthalmology at David Geffen School of Medicine, UCLA, Doheny Eye Institute, made a pair of presentations at the Association for Research in Vision and Ophthalmology annual meeting in New Orleans. He offers some of the highlights in a conversation with Ophthalmology Times.
Read More
ARVO LIVE: CEO of RetinAI gives update on technological advances in ophthalmology
May 2nd 2023Ophthalmology Times® talked with Carlos Ciller, PhD, the co-founder and CEO of RetinAI, about technological advances the company is making to drive innovation and to accelerate drug development pipelines at this year's ARVO meeting.
Read More
ARVO LIVE: AI revolution in ophthalmology
May 2nd 2023Ophthalmology Times® talked with AnnMarie Hipsley, DPT, PhD, about 3D finite element model used to understand more about the biomechanics of accommodation and dis-accommodation as it relates to functions for visual function as well as aqueous hydrodynamics at this year's ARVO meeting.
Read More
ARVO LIVE: Epigenetic reprogramming to reverse aging and restore function to retinal ganglion cells
April 27th 2023Ophthalmology Times® talked with Bruce Ksander, PhD, about epigenetic reprogramming to reverse aging and restore function to retinal ganglion cells at this year's ARVO meeting.
Read More
ARVO LIVE: Lamina cribrosa pressure and predicting structural glaucoma progression
April 26th 2023Ophthalmology Times® talked with Ronald Zambrano, lab supervisor for the advanced Ophthalmic Imaging Lab at NYU Langone about lamina cribrosa pressure and predicting structural glaucoma progression at this year's ARVO meeting.
Read More
ARVO LIVE: Trefoil Therapeutics CEO gives update on TTHX1114 in patients with FECD
April 24th 2023Ophthalmology Times® talked with David Eveleth, MD, CEO and Founder of Trefoil Therapeutics about TTHX1114 in patients with Fuchs endothelial corneal dystrophy (FECD) undergoing Descemet’s Stripping Only (DSO) in combination with cataract surgery at this year's ARVO meeting.
Read More